QVAR SUMMARY
The active component of QVAR 40 mcg Inhalation Aerosol and QVAR 80 mcg Inhalation Aerosol is beclomethasone dipropionate, USP, an anti-inflammatory corticosteroid having the chemical name 9-chloro-11(beta),17,21-trihydroxy-16(beta)-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate.
QVAR is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for the systemic corticosteroids.
Beclomethasone dipropionate is NOT indicated for the relief of acute bronchospasm.
|
NEWS HIGHLIGHTSMedia Articles Related to Qvar (Beclomethasone Inhalation)
beclomethasone inhaler, Qvar
Source: MedicineNet Lungs Design And Purpose Specialty [2009.03.11]
Title: beclomethasone inhaler, Qvar
Category: Medications
Created: 3/2/2005
Last Editorial Review: 3/11/2009
Asthma Combo Seems Less Influenced by Genes (HealthDay)
Source: Y! Health Asthma News [2009.11.19]
HealthDay - THURSDAY, Nov. 19 (HealthDay News) -- People's genetic makeup has
been shown to affect how they respond to asthma medications, but a new
study finds that many people respond well to a particular combination
treatment regardless of their genes.
Annals Of Allergy, Asthma And Immunology To Be Published By Elsevier
Source: Allergy News From Medical News Today [2009.11.18]
Elsevier is pleased to announce that beginning with Volume 104 (2010) it will assume publication of the Annals of Allergy, Asthma & Immunology, the official journal of the American College of Allergy, Asthma & Immunology (ACAAI). The i>Annals of Allergy, Asthma & Immunology, published since 1942, will continue under the leadership of Editor Gailen D. Marshall, MD, PhD and a distinguished editorial board.
Folic Acid Late in Pregnancy Tied to Asthma in Kids
Source: MedicineNet Asthma Specialty [2009.11.16]
Title: Folic Acid Late in Pregnancy Tied to Asthma in Kids
Category: Health News
Created: 11/13/2009 2:10:00 PM
Last Editorial Review: 11/16/2009
New Research Shows Over-use Of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention
Source: Respiratory / Asthma News From Medical News Today [2009.11.13]
Research presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting shows that an intervention to reduce over-dispensing and waste of asthma medications can succeed without compromising patient safety and can result in substantial cost savings. Medco Health Solutions, Inc.
Published Studies Related to Qvar (Beclomethasone Inhalation)
A randomized study comparing the effect of loratadine added to montelukast with montelukast, loratadine, and beclomethasone monotherapies in patients with chronic asthma. [2009.06]
CONCLUSION: In this study, the addition of loratadine to montelukast produced a small numerical, but not statistically significant, improvement in FEV(1) and, in general, no consistent improvement in other asthma endpoints. No improvement of montelukast + loratadine versus beclomethasone was seen in any endpoint.
A randomized, controlled trial to investigate the effect of ciclesonide and beclomethasone dipropionate on eye lens opacity. [2008.12]
BACKGROUND: Inhaled corticosteroids (ICS) are recommended first-line therapy for the treatment of persistent asthma. However, reports from observational studies have suggested that the use of ICS may be associated with systemic adverse events, such as glaucoma and cataract (opacity of the lens) formation. OBJECTIVE: To compare two ICS over 1 year regarding the formation/progression of lenticular opacities in patients with asthma... CONCLUSIONS: Mean changes in LOCS III scores were very small in both groups. Treatment with ciclesonide 640 micro g/day or beclomethasone dipropionate 640 micro g/day for 1 year has a minimal impact on lenticular opacities development and/or progression.
Beclomethasone inhaler versus intravenous lidocaine in the prevention of postoperative airway and throat complaints: a randomized, controlled trial. [2008.01]
BACKGROUND AND OBJECTIVE: Previous reports indicate that inhaled corticosteroids attenuate airway inflammation. Beclomethasone inhaler was highly effective in the prevention of postoperative airway symptoms. Intravenous lidocaine prior to endotracheal intubation has also been shown to decrease the incidence of postoperative sore throat and cough. The aim of the present study was to compare the effect of beclomethasone inhaler with various clinically used dosages of intravenous lidocaine prior to endotracheal intubation on the incidence and severity of postoperative sore throat, cough, sputum, hoarseness, and dysphagia... CONCLUSION: Beclomethasone inhaler is comparable with intravenous lidocaine prior to intubation in decreasing postoperative sore throat and cough. In addition, beclomethasone inhaler decreases the incidence and severity of postoperative sputum.
Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. [2008]
The corticosteroid beclomethasone dipropionate (BDP) has been formulated with the long acting beta agonist formoterol (BDP/formoterol 100 microg/6 microg, Foster) in a single inhaler using Modulite technology... The BDP/formoterol combination was well tolerated, and exhibited a safety profile generally similar to formoterol alone when administered in high doses to stable asthmatic patients.
Efficacy and safety of once or twice daily inhalation of extrafine HFA beclomethasone dipropionate in patients with mild to moderate asthma. [2007.11]
The relatively new chlorofluorocarbon-free solution preparation of beclomethasone dipropionate in hydrofluoroalkane (HFA-BDP) (Qvar, 3M Pharmaceuticals) generates an extra fine aerosol with a smaller particle size (mean mass aerodynamic diameter of 1.1 microm), drug deposition in the lung is more uniformly distributed, thus improving efficacy even at a low dose...
Clinical Trials Related to Qvar (Beclomethasone Inhalation)
Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children [Completed]
The primary objective of this study is to compare the QVAR-Easi-Breathe 100 mcg/day and
QVAR-Easi-Breathe 200 mcg/day with placebo relative to changes in forced expiratory volume in
1 second (FEV1) results following 12 weeks of treatment. Secondary objectives such as daily
asthma symptoms scores (per week), morning peak expiratory flow (PEF) values, nocturnal
awakening and utilization of rescue medication per day also will be evaluated. In addition,
an exploratory evaluation will assess the comparability of the two devices (i. e.,
QVAR-Easi-Breathe versus QVAR-MDI) at the same dose levels.
Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms [Completed]
To demonstrate a superior efficacy of BDP plus rescue salbutamol suspension for nebulisation,
compared to placebo plus rescue salbutamol, in the relief of symptoms of asthma in young
children with persistent symptoms of asthma.
The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease [Terminated]
This is an investigator-sponsored research study to evaluate if treatment with HFA-134a
beclomethasone (QVAR) has an effect on peripheral (or outer) airway inflammation and airway
“remodeling” or scarring in subjects with COPD. Approximately 20 subjects with COPD will
participate for approximately 7 weeks, with 10 receiving an active (BDP) inhaler with
HFA-134a and 10 receiving a placebo.
Rosiglitazone Versus Theophylline in Asthmatic Smokers [Completed]
Asthmatic smokers display a blunted response to both inhaled and oral corticosteroid
treatments and are at increased risk for exacerbations and near fatal asthma. The prevalence
of smoking in asthmatics runs between 20-30%. Therefore, new, more efficacious treatments are
required.
Recent work has demonstrated a mechanism which may explain steroid resistance. A commonly
used drug called theophylline can reverse this steroid resistance in laboratory studies.
Another commonly used drug, rosiglitazone can reverse smoking induced lung inflammation in
laboratory studies.
The investigators aim to study the effects of these drugs on smoking asthmatics' lung
function and other parameters including quality of life and asthma control.
The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry [Completed]
Background Chronic inflammation in peripheral airways plays an important role in the
pathophysiology of asthma. Extrafine hydrofluoroalkane (HFA) beclometasone is distinguished
from other ICS because of its fine aerosol characteristics. As a result, there is a greater
extent of deposition of extrafine HFA-beclometasone in the peripheral airways. Therefore,
extrafine HFA-beclometasone may have an extra anti-inflammatory effect in children with
asthma.
Aim To analyse the potential extra anti-inflammatory effect of extrafine HFA-beclometasone
compared to HFA-flucticasone in children with asthma by means of alveolar nitric oxide (NO)
concentration and bronchial NO flux, inflammatory markers in exhaled breath condensate (EBC),
and conventional parameters.
Method In a cross-over study design of 6 months, 33 children, aged 6-12 years, with doctor
diagnosed mild persistent asthma, were treated with extrafine HFA-beclometasone inhaled from
an autohaler and HFA-flucticasone inhaled from a discus. Primary outcome parameters of this
study were; alveolar NO concentration and bronchial NO flux. Secondary outcome parameters
were inflammatory markers in EBC, lung function parameters, symptoms, presence and duration
of exacerbations and adverse effects. All parameters were recorded at baseline and after each
treatment period.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Qvar has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| | Qvar review by 56 year old female patient | | | Rating |
| Overall rating: | |  |
| Effectiveness: | | Highly Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | asthma |
| Dosage & duration: | | 80mcg (dosage frequency: day and night) for the period of 5 years |
| Other conditions: | | None |
| Other drugs taken: | | None | | |
Reported Results |
| Benefits: | | The treatment benefits of QVAR are that I do not think about my condition. Also, it is easy to execute the treatment. I exercise and go about my day as if I were not afflicted with asthma. I do not worry about having an attack, which is a big relief. The treatment is inconspicuous, another plus. |
| Side effects: | | I am fortunate in saying that there are no side effects at the dose I am taking. |
| Comments: | | Each morning, I take out my AeroChamber that holds the QVAR. I shake the QVAR aerosol canister and place it back into the AeroChamber. I then empty my lungs of air and take a big puff of the QVAR. I hold it in my lungs for as long as possible before breathing out. I repeat this process at night before retiring. I expect to be using QVAR for the foreseeable future. |
|
|
|
Page last updated: 2009-11-19
|
